Characteristics of long-term survivors following CART infusion for B-ALL (n = 25)
| Characteristics . | N . | % or range . |
|---|---|---|
| General pre-CART demographics | ||
| Median age (at CART infusion) in years | 12 | 5-34 |
| Sex, female | 5 | 20 |
| Median of pre-CART lines of therapy (excluding HCT) | 3 | 1-9 |
| Patients who received prior HCT | 4 | 16% |
| LTFU outcomes | ||
| Median follow-up time, y (range) | 7.3 | 3-11 |
| Median age (at present) in years | 22 | 10-38 |
| Patients who received post-CART HCT | 24 | 96 |
| Patients with new primary cancer | 3 | 12 |
| Patients with new neurologic disorder | 5 | 20 |
| Patients with new autoimmune disorder | 0 | 0 |
| Patients with recent significant infections∗ | 0 | 0 |
| Patients with an ongoing hematologic disorder | 0 | 0 |
| Patients with a concurrent other disorder or illness | 17 | 68 |
| Patients who are on any medications at last follow-up | 17 | 68 |
| Characteristics . | N . | % or range . |
|---|---|---|
| General pre-CART demographics | ||
| Median age (at CART infusion) in years | 12 | 5-34 |
| Sex, female | 5 | 20 |
| Median of pre-CART lines of therapy (excluding HCT) | 3 | 1-9 |
| Patients who received prior HCT | 4 | 16% |
| LTFU outcomes | ||
| Median follow-up time, y (range) | 7.3 | 3-11 |
| Median age (at present) in years | 22 | 10-38 |
| Patients who received post-CART HCT | 24 | 96 |
| Patients with new primary cancer | 3 | 12 |
| Patients with new neurologic disorder | 5 | 20 |
| Patients with new autoimmune disorder | 0 | 0 |
| Patients with recent significant infections∗ | 0 | 0 |
| Patients with an ongoing hematologic disorder | 0 | 0 |
| Patients with a concurrent other disorder or illness | 17 | 68 |
| Patients who are on any medications at last follow-up | 17 | 68 |
Recent significant infections were those that occurred within the past year (data cutoff: 1 June 2025)